# Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential

> **NCT02419378** · PHASE4 · COMPLETED · sponsor: **University Hospital Muenster** · enrollment: 15 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Alemtuzumab

## Key facts

- **NCT ID:** NCT02419378
- **Lead sponsor:** University Hospital Muenster
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2020-07
- **Final completion:** 2020-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02419378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02419378, "Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02419378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*